Mani Mohindru, Novasenta CEO

Ex­clu­sive: UPMC launch­es an­oth­er biotech, root­ed in the tu­mor mi­croen­vi­ron­ment

In Mani Mo­hin­dru’s telling, No­vasen­ta is “as biotech-y as you can get.”

The CEO of the lat­est start­up out of UPMC’s sprawl­ing re­search ap­pa­ra­tus says her biotech is look­ing for nov­el tar­gets to make new can­cer ther­a­pies, as com­pared to the pro­lif­er­a­tion of biotechs pop­ping up with pro­grams go­ing against tar­gets that are al­ready val­i­dat­ed or in the pub­lic do­main.

The com­pa­ny has se­cured $40 mil­lion in Se­ries A funds led by the Pitts­burgh in­sti­tu­tion, based on 10 years of work out of the Hill­man Can­cer Cen­ter’s Tu­mor Mi­croen­vi­ron­ment Cen­ter. Three pro­grams have been pro­pelled to cen­ter stage, with one or two of them slat­ed for IND-en­abling stud­ies lat­er next year with the aim of clin­i­cal tri­als kick­ing off in 2024, Mo­hin­dru told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.